Category: Latest News

Asbury Automotive Group (NYSE:ABG) reported second-quarter earnings on Tuesday that surpassed analyst forecasts, driven by strong profitability despite slightly lower-than-expected revenue. Shares rose 1.75% in pre-market trading following the announcement. The automotive retailer posted adjusted earnings of $7.43 per diluted share, well above the $6.83 consensus estimate. Revenue came in at $4.4 billion, a bit…

Union Pacific Corporation (NYSE:UNP) announced Tuesday it will acquire rival Norfolk Southern Corporation (NYSE:NSC) in a cash-and-stock transaction valued at $320 per share, aiming to form the first transcontinental railroad in the U.S. The offer represents a 25% premium over Norfolk Southern’s 30-day volume-weighted average price as of July 16. Following the announcement, Union Pacific…

Exelixis Inc. (NASDAQ:EXEL) shares dropped more than 12% in pre-market trading Tuesday following its Q2 earnings report and the announcement to discontinue development of its experimental cancer drug zanzalintinib in a head-and-neck cancer trial. For the quarter ending June 30, 2025, Exelixis reported total revenues of $568.3 million, including $520.2 million in net product revenues…

Fulcrum Therapeutics Inc. (NASDAQ:FULC) saw its stock drop 17% on Tuesday, wiping out earlier gains following the release of data from the 12 mg dose cohort in its Phase 1b PIONEER trial of pociredir for sickle cell disease. The Cambridge, Massachusetts-based biopharma reported an absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline after…

Alkermes plc (NASDAQ:ALKS) reported stronger-than-expected second-quarter results on Tuesday, driven by solid performance across its proprietary product lineup. Shares rose 5.16% in pre-market trading after the announcement. The biopharmaceutical firm posted adjusted earnings of $0.52 per share, well above the $0.36 consensus estimate. Revenue totaled $390.7 million, beating expectations of $347.16 million despite a 2.1%…

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw its stock soar 12% after the U.S. Food and Drug Administration (FDA) granted approval for EMPAVELI® (pegcetacoplan), the first approved therapy for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 and older. This approval represents a major advance for individuals affected by these rare…

Corning Incorporated (NYSE:GLW) saw its shares rise 2.45% in pre-market trading Tuesday after reporting better-than-expected second-quarter results fueled by high demand for products linked to artificial intelligence. The materials science firm posted core earnings per share of $0.60 for the quarter, surpassing the analyst forecast of $0.57. Revenue reached $4.05 billion, beating estimates of $3.86…

Shares of Bakkt Holdings Inc. (NYSE:BKKT) plummeted 39% after the digital asset firm announced pricing for a public stock offering that significantly undercut its previous market value. The offering, priced at $10 per share, is well below Monday’s closing price of $17.17. Bakkt is issuing 6,753,627 shares of Class A common stock along with pre-funded…

Johnson Controls International plc (NYSE:JCI) posted adjusted earnings for its fiscal third quarter that narrowly surpassed analyst expectations, though shares slipped 2.26% in pre-market trading on Tuesday as investors weighed regional inconsistencies in performance. The smart building technology firm reported adjusted earnings per share of $1.05, topping the consensus estimate of $1.01. Revenue came in…

PJT Partners Inc. (NYSE:PJT) delivered strong second-quarter results on Tuesday, surpassing analyst expectations and setting a new revenue record, fueled by robust growth in its strategic advisory business. The firm reported adjusted earnings of $1.54 per share for the quarter, beating the consensus estimate of $1.36. Revenue climbed to $406.9 million, outpacing forecasts of $379.17…